23.99% of Gyre Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Gyre Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company	Details
5/10/2024	Vanguard Group Inc.	195,098	$3.41M	0.0%	-1.5%	0.228%

Data available starting January 2016

Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.

Today's Range

Now: $11.72

$11.62

$12.24

50 Day Range

MA: $12.62

$9.36

$17.11

52 Week Range

Now: $11.72

$4.80

$30.40

Volume

19,179 shs

Average Volume

89,157 shs

Market Capitalization

$1.00 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.12

Who are the company insiders with the largest holdings of Gyre Therapeutics?: Gyre Therapeutics' top insider investors include:
Nassim Usman (Director)
Learn More about top insider investors at Gyre Therapeutics.